Massachusetts Financial Services Co. MA Boosts Holdings in Health Catalyst, Inc. (NASDAQ:HCAT)

Massachusetts Financial Services Co. MA raised its holdings in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 17.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 331,847 shares of the company’s stock after buying an additional 50,297 shares during the period. Massachusetts Financial Services Co. MA owned about 0.56% of Health Catalyst worth $2,121,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in HCAT. Principal Financial Group Inc. increased its stake in shares of Health Catalyst by 6.9% in the 2nd quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock worth $188,000 after purchasing an additional 1,907 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Health Catalyst by 6.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 49,746 shares of the company’s stock valued at $375,000 after purchasing an additional 2,831 shares during the period. ClariVest Asset Management LLC increased its position in Health Catalyst by 1.2% in the second quarter. ClariVest Asset Management LLC now owns 285,627 shares of the company’s stock worth $1,825,000 after buying an additional 3,302 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Health Catalyst by 461.0% in the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after buying an additional 5,232 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of Health Catalyst by 9.1% during the 2nd quarter. Rhumbline Advisers now owns 91,111 shares of the company’s stock valued at $582,000 after buying an additional 7,589 shares in the last quarter. 85.00% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Health Catalyst

In related news, COO Daniel Lesueur sold 5,208 shares of the stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $6.15, for a total transaction of $32,029.20. Following the sale, the chief operating officer now owns 155,215 shares in the company, valued at approximately $954,572.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, COO Daniel Lesueur sold 5,208 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $6.15, for a total value of $32,029.20. Following the completion of the sale, the chief operating officer now owns 155,215 shares in the company, valued at approximately $954,572.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the transaction, the insider now owns 255,881 shares in the company, valued at $1,847,460.82. The disclosure for this sale can be found here. Insiders have sold a total of 35,361 shares of company stock worth $248,033 over the last ninety days. Company insiders own 2.70% of the company’s stock.

Health Catalyst Stock Performance

Shares of HCAT opened at $8.69 on Monday. The stock has a market capitalization of $513.01 million, a PE ratio of -4.70 and a beta of 1.31. The company’s fifty day moving average is $7.29 and its 200 day moving average is $6.89. Health Catalyst, Inc. has a fifty-two week low of $5.42 and a fifty-two week high of $11.41.

Health Catalyst (NASDAQ:HCAT) last posted its earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.04. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The firm had revenue of $75.90 million for the quarter, compared to the consensus estimate of $74.96 million. During the same period in the previous year, the firm posted ($0.21) EPS. The business’s quarterly revenue was up 3.7% on a year-over-year basis. As a group, research analysts forecast that Health Catalyst, Inc. will post -0.35 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Evercore ISI reduced their target price on shares of Health Catalyst from $9.00 to $8.00 and set an “outperform” rating for the company in a report on Tuesday, July 9th. Stephens lowered their target price on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research note on Friday. JPMorgan Chase & Co. boosted their price objective on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Finally, Piper Sandler dropped their price objective on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 26th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.42.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.